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Abstract
Context
Genetic variation in human maternal DNA contributes to the susceptibility for development
of gestational diabetes mellitus (GDM).
Objective
We assessed 77 maternal single nucleotide gene polymorphisms (SNPs) for associations
with GDM or plasma glucose levels at OGTT in pregnancy.
Methods
960 pregnant women (after dropouts 820: case/control: m99’WHO: 303/517, IADPSG: 287/
533) were enrolled in two countries into this case-control study. After genomic DNA isolation
the 820 samples were collected in a GDM biobank and assessed using KASP (LGC Geno-
mics) genotyping assay. Logistic regression risk models were used to calculate ORs accord-
ing to IADPSG/m’99WHO criteria based on standard OGTT values.
Results
The most important risk alleles associated with GDM were rs10830963/G of MTNR1B (OR =
1.84/1.64 [IADPSG/m’99WHO], p = 0.0007/0.006), rs7754840/C (OR = 1.51/NS, p = 0.016)
of CDKAL1 and rs1799884/T (OR = 1.4/1.56, p = 0.04/0.006) of GCK. The rs13266634/T
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(SLC30A8, OR = 0.74/0.71, p = 0.05/0.02) and rs7578326/G (LOC646736/IRS1, OR = 0.62/
0.60, p = 0.001/0.006) variants were associated with lower risk to develop GDM. Carrying a
minor allele of rs10830963 (MTNR1B); rs7903146 (TCF7L2); rs1799884 (GCK) SNPs were
associated with increased plasma glucose levels at routine OGTT.
Conclusions
We confirmed the robust association of MTNR1B rs10830963/G variant with GDM binary
and glycemic traits in this Caucasian case-control study. As novel associations we report
the minor, G allele of the rs7578326 SNP in the LOC646736/IRS1 region as a significant
and the rs13266634/T SNP (SLC30A8) as a suggestive protective variant against GDM
development. Genetic susceptibility appears to be more preponderant in individuals who
meet both the modified 99’WHO and the IADPSG GDM diagnostic criteria.
Introduction
Abnormal glucose tolerance first recognized during pregnancy is defined as gestational diabe-
tes mellitus (GDM). The estimated prevalence of GDM varies according to the study popula-
tion and diagnostic criteria. A plethora of different GDM classification methods and diagnostic
guidelines are available [1]. Prevalence estimates of gestational diabetes mellitus indicate that it
is a common disease in developed countries with a prevalence ranging from 8.1–14.8% in Hun-
gary (HUN) [2] and>10% in Austria (AT) [1], depending on the diagnostic criteria applied.
Pregnancy is generally characterized by increased adiposity and increased insulin resis-
tance. Insulin resistance during pregnancy occurs partially due to the increased production
of human placental lactogen, estrogen and prolactin especially in the second and third trimes-
ters and also due to weight gain. Individuals with limited beta cell response to compensate for
physiologically increased insulin resistance are more prone to develop GDM.
Due to the trends in modern societies the more prevalent clinical risk factors, such as higher
pre-pregnancy body mass index (BMI) [3] and advanced age [4] at pregnancy resulted in
increased insulin- resistance and a need for a compensatory increase in beta cell response. In
line with this the prevalence of GDM started to increase sharply in the early 90s [4].
The role for genetic factors in disease development is confirmed by findings that women
with a diabetic sibling have an 8.4-fold increased risk of GDM [5]. Since beta cell dysfunction
is known to play a critical role in GDM [6, 7] recent evidence from a twin study demonstrating
a 75% heritability in insulin secretion variability in younger adults [8] underlines the impor-
tance of genetic components in the development of GDM.
As GDM and type 2 diabetes mellitus (T2D) share similarities in their pathogenesis with
respect to impaired insulin secretion and increased insulin resistance, research efforts focused
on mapping their genetic properties. These studies demonstrated that GDM and T2D share
common genetic background, with similar magnitude of effect sizes on the same risk alleles
[9]. A few authors even suggested that GDM and type 2 diabetes are two aspects of the same
entity [10]
Despite the number of genome wide associations studies (GWAS) performed and reports
on associations for selected genotypes in GDM, the protective and risk genetic loci of GDM are
still not fully elucidated [9, 11–17]. This might be due to differences in the study populations
(ethnicity), small sample size and the different diagnostic criteria used. Most of the GWAS
Novel Genetic Associations in GDM
PLOS ONE | DOI:10.1371/journal.pone.0169781 January 10, 2017 2 / 17
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
studies in this disease were conducted in Asian populations [11], highlighting the need for con-
firmation in Caucasian populations [18].
In our study, we aimed to identify maternal gene variants that are associated with GDM or
influence fasting and 2-hour glucose levels after a routine 75 g oral glucose tolerance test
(OGTT) during pregnancy (24-28th gestational week [gw]). A set of 77 gene variants single
nucleotide polymorphisms (SNPs) were selected and the majority of these variants were com-
mon variants previously reported to be associated with either T2D, GDM or with important
metabolic traits, such as hemoglobin A1c levels, fasting and 2 hour plasma glucose levels, insu-
lin-resistance indices, proinsulin levels or with other related traits such as the BMI [19]. We
compared the impact of two different diagnostic criteria of GDM on the association of gene
variants with GDM. In Austria, we used the International Association of the Diabetes and
Pregnancy Study Groups (IADPSG) criteria [GDM: 75gCH OGTT at 24–28 gw: fasting plasma
glucose (FPG)5.1mmol/L, 60 min plasma glucose (PG)10.0 mmol/L, 120 min PG8.5
mmol/L], while the Hungarian centers used the modified 1999 World Health Organization
(WHO) recommendation [GDM: 75gCH OGTT at 24–28 gw: FPG6.1 mmol/L, 120 min
PG7.8 mmol/L].
We assessed T2D susceptibility gene variants to confirm the interrelated genetic back-
ground of GDM in a Caucasian population. We also hypothesized, that patient selection by
different diagnostic criteria in GDM might influence the results of the genetic association
study, as different threshold values in OGTT can have an influence on patient distribution
between the control (CNTRL) and GDM group and thus could represent a bias if remains
without adjustment.
Our results support the conception of a similar genetic background to GDM and T2D,
however there are variances in the effect sizes of the risk/protective SNPs in between the two
diseases. We confirmed the robust role of rs10830963/G of Melatonin receptor 1B (MTNR1B)
gene variant in developing GDM or glycemic traits. Furthermore, we identified two novel
associations, namely the minor, G allele of the rs7578326 SNP in the LOC646736/IRS1region
as a significant, and the rs13266634/T SNP Solute carrier family 30 member 8 (SLC30A8) as a
suggestive protective variant against GDM development. According to our findings, the minor
allele frequency of the known common causal MTNR1B variant, rs10830963 is significantly
higher in the GDM subgroup which meet both the modified 99’ WHO and the IADPSG diag-
nostic criteria.
Materials and Methods
Patients
The institutional (Semmelweis University, Regional and Institutional Committee of Science
and Research Ethics and Ethics Committee of the Medical University of Vienna) and the
national ethical bodies of Hungary (Medical Research Council Scientific and Research Com-
mittee) and Austria (Federal Office for Safety and Health care) have approved the study, which
was conducted according to the declaration of Helsinki. Pregnant women were enrolled to the
study after signing the informed consent for the whole project and a special consent for storing
their samples in a biobank for use in anonymized genetic studies.
Patients were recruited from two Hungarian and a single Austrian centers in the framework
of the European Foundation for the Study of Diabetes New Horizons initiative.
Inclusion criteria
The diagnosis of GDM (inclusion criteria) has been established according to the national rec-
ommendations of the two countries: the Austrian study center applied the IADPSG criteria
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[GDM: 75gCH OGTT at 24–28 gw: FPG5.1mmol/L, 60 min PG10.0 mmol/L, 120 min
PG8.5 mmol/L], while the Hungarian centers used the modified 1999 WHO recommenda-
tion [GDM: 75gCH OGTT at 24–28 gw: FPG6.1 mmol/L, 120 min PG7.8 mmol/L] [20,
21].
Exclusion criteria
Exclusion criteria were based in part on the STrengthening the Reporting of observational
(case-control) studies in Epidemiology statement for Genetic Association studies (STREGA)
guidelines [22]. In addition we excluded patients with: diabetes in pregnancy (i.e. overt diabe-
tes)and diabetes categories other than GDM (e.g.: autoimmune), any apparent major disease
or chronically treated with medication with known impact on glycemic control, in vitro fertili-
zation, missing major clinical data, twin pregnancies or variables likely to be associated with
population stratification (e.g.: non-European ancestry).
Clinical data collection
We collected all relevant clinical information that was used in the case- control study or quali-
tative trait assessments, including the result of the OGTT, pre-pregnancy BMI, maternal age
and the birth-weight percentiles [23].
Research design
As two different diagnostic GDM criteria were applied (IADPSG or the modified 99’ WHO) in
the two participating countries the following protocol was employed for the analysis of geno-
type associations: we first had to reclassify the entire dataset of the whole study population
according to both criteria based on the OGTT results (FPG and 2 hour PG values) as a ‘diagno-
sis stratification procedure’. This was possible since there was no medical intervention prior to
the 75g OGTT and the test itself was performed in the standardized time-frame of gestation
(24th-28th gestational week). Those individuals in whom the GDM diagnosis was established
exclusively on the basis of the 60 min OGTT result remained in the GDM group in the ‘diag-
nosis stratification procedure’. Such cases are rare (less than 5.7% according to the Hyperglyce-
mia and Adverse Pregnancy Outcomes (HAPO) Study [24] and 13% in the participating
Austrian study population). We have performed all binary analysis twice, first using the 99’
modified WHO criteria and second using the IADPSG criteria.
A set of 77 SNPs were selected based on the results of prior genome wide association studies
(GWAS) on T2D, BMI, Insulin resistance (IR), Insulin secretion/ beta cell function, plasma
glucose or serum insulin level traits. Functionally, the reported genes were suggested to be
implicated in the incretin effect, beta-cell function or genesis, potassium channel function,
amyloid formation, zinc transport, insulin resistance, obesity development, insulin-like growth
factor (IGF) system, vessel formation, glucose homeostasis, circadian rhythm, neuronal regula-
tion of appetite, energy balance or immunoregulation (S1 Table).
Subsequently we provided two numerically different odds ratios and p-values for each gene
variants that were significantly associated with GDM according to the corresponding diagnos-
tic system applied in the analysis.
Genomic DNA isolation and genotyping
Genomic DNA was isolated using a magnetic bead based robotized approach (Hamilton
Robotics, Magna Starlet, Bonaduz, Switzerland) from EDTA-anticoagulated whole blood sam-
ples obtained from cubital veins. Kompetitive Allele Specific PCR (KASP™) genotyping (FRET
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[fluorescence resonant energy transfer] based assay) (LGC Genomics, Teddington, Middlesex,
UK) was used for the bi-allelic discrimination of 77 SNPs. The overall call rate for all SNPs
assessed exceeded the 97% and no discordant genotypes were identified in the control samples
of which genomic DNA were isolated in two different runs and subsequently genotyped sepa-
rately in duplicates for all SNPs. Results were presented using the SNP viewer software (version
1.99, Hoddesdon, UK) and genotype data were extracted for statistical analysis.
Statistical analysis
GDM as binary trait. All statistical analyses of this case-control study were carried out in
a specially designed program in R-project language. We first analyzed associations between
genotypes according to the 77 assessed SNPs and the diagnosis of gestational diabetes mellitus
as a case-control study. As the diagnosis of GDM was originally established according to crite-
ria (IADPSG or modified 99’ WHO) which was used in the center of the patient care provider,
we first had to reclassify the entire dataset of the whole study population according to both cri-
teria based on the OGTT results (FPG and 2 hour PG values) as a ‘diagnosis stratification pro-
cedure’. Subsequently, we analyzed the data using the logistic regression method under both
the dominant and the additive genetic models. We calculated odds ratio (OR), statistical
power and p-value for every SNP and used the Benjamini-Hochberg p-correction method to
minimize false discovery. ORs were reflective for the Effect Sizes in our case-control study for
binary outcomes and were calculated to represent the effects of carrying the reported minor
alleles under the dominant model or the effect of the minor allele under the additive genetic
model (S2 Table). Subsequently minor allele frequencies were also calculated for each 77 SNPs
assessed (S3 Table).
We adjusted our result to the maternal age and pre-pregnancy BMI (S2 Table, Panel A) as
covariates in both models, provided that there were no published prior data or direct result in
this analysis for the association between the assessed SNPs and pre-pregnancy BMI. If an asso-
ciation between the SNP assessed and pre-pregnancy BMI was observed then only age was
used as covariate in adjustment calculations.
Due to that an effect through the causative chain still can be a potential risk for disease
development and that BMI-adjustment might possibly be important even if there is a signifi-
cant SNP-BMI association we reported the p-values and ORs for each 77 SNPs association
with GDM one adjusted for age (S2 Table, Panel B) and additionally adjusted for age and
pre-pregnancy BMI also (S2 Table, Panel A). However the literature suggests to use the
adjusted data by age and BMI as these are often neglected confounders and concludes that this
approach results in a more accurate analysis compared to the direct use of unadjusted raw data
[18]. Therefore—after exclusion of the causative chain for our most significant findings—we
indicate these genetic association results adjusted by age and BMI. Deviations from the Hardy-
Weinberg equilibrium in the genotype distributions were assessed for all SNPs using Chi
Squared test (S4 Table). We used post-hoc analysis for power calculation. From the p value
and statistical power we calculated the exact probability of the existing effect for each gene var-
iant associated significantly with GDM.
Glycemic traits. In addition we performed analysis for the associations between geno-
types according to 77 assessed SNPs and glycemic traits, such as the fasting and 2 hour plasma
glucose levels at OGTT and pre-pregnancy BMI using linear regression both under the addi-
tive and also under the dominant genetic models. Coefficient values were calculated for signifi-
cantly associated SNPs in the glycemic trait analysis representing effect sizes both on the
fasting and the 2-hour plasma glucose levels and expressed in mmol/L.
Novel Genetic Associations in GDM
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To further improve the applied statistics we also re-analyzed our data using a bootstrap
resampling method for the linear regression to confirm results when the glycemic traits were
analyzed. The bootstrap application was used due to that it is a statistically appropriate way to
control and check the stability of the results.
All data were assessed according to the guidelines of STREGA which is an extension of the
STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement
[22].
Clinical characteristics. Both the Shapiro—Wilks and the Kolmogorov—Smirnov tests
were used to assess normality. Mann—Whitney U-test (MWU) was used to compare means
and detect differences in case of nonparametric distributions, and 2-tailed t-test with indepen-
dent variables was used when the distribution was normal. For this re-classified analysis of
clinical data we have used Welch-test for comparisons between the countries as the standard
deviation (SD) values were not known (and distributions of these parameters are usually
asymptotic normal in literature). The, U‘ test was performed with two-sided counterhypothesis
due to that we did not hypothesize difference between the two countries.
Results
Altogether 960 pregnant women were enrolled to the study. Dropouts due to insufficient sam-
pling and withdrawn consent eventually reduced the final sample size to 820. Out of the 820,
303 would be diagnosed with GDM according to the 99’ modified WHO criteria and 287
according to the IADPSG criteria. The clinical characteristics of the pregnant population stud-
ied are indicated in Table 1.
The clinical data (0 min and 120 min plasma glucose values at 75g OGTT, pre-pregnancy
BMI, age) were also reclassified according both the IADPSG and m99‘ WHO criteria for the
entire (joint Austrian and Hungarian) study population (S5 Table).
In addition to the differences in the plasma glucose values at OGTT significant differences
were detected in pre-pregnancy BMI and age at delivery between the GDM and control popu-
lations in both countries. We also found differences in the 0’ PG values (HUN>AT, 4.52mM
vs. 4.38mM, p<0.05), weight gain during pregnancy in the controls (HUN>AT 13.80kg vs.
9.47kg, p<0.05) and in the 0’ PG (AT>HUN 5.14mM vs. 4.96mM, p<0.05) and 120’ PG
(HUN>AT 8.72mM vs.7.38mM, p<0.05) values and age at delivery (HUN>AT 33.7 years vs.
32.04 years, p< 0.05) between the GDM groups of the two countries. However differences in
the clinical characteristics between Austria and Hungary are unlikely to affect the genetic
study as the clinical characteristics were compared using the country designated diagnosis as
grouping variable, in contrast to the genetic analysis, when we regrouped the study population
based on the 75g OGTT results according to both GDM diagnostic criteria.
Associations found at significant or suggestive levels in the case-control analysis are indi-
cated in Table 2. There was no significant deviation from the Hardy-Weinberg equilibrium
(S4 Table) in the genotype distributions of SNPs with significant results.
GDM as binary trait
Association ofMTNR1B rs10830963 with GDM. The most significant findings were
related to the rs10830963 polymorphism of the melatonin receptor 1B (MTNR1B): carrying a
G allele of the rs10830963 polymorphism of the MTNR1B significantly increased the risk of
developing GDM (Table 2) in our case-control study.
The associations of rs10830963 with GDM binary trait resulted in better significance
(IADPSG / m99’WHO p: 7x10-4/6x10-3) and higher odds ratios (ORs: 1.84/1.64) under the
dominant model compared to the additive model (p: 0.003/0.012, OR: 1.48/1.39, respectively)
Novel Genetic Associations in GDM
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after adjustment to maternal age and pre-pregnancy BMI covariates. This association
remained significant under the dominant model, when adjusted p-values were further cor-
rected using the Benjamini-Hochberg (B-H) method. Accordingly, minor allele frequencies
(MAF) were higher in the GDM groups than in the control groups under each diagnostic crite-
ria applied (IADPSG: 36% vs. 28%, m99’WHO: 36% vs. 28%; GDM vs. Control groups respec-
tively, Table 2).
Carrying the G risk allele of the MTNR1B rs10830963 in any form was associated with sub-
stantially higher odds of disease development in the group of patients who could meet both the
m99’ WHO and the IADPSG criteria (OR: 2.05, p<10−4, z statistic: 4.17) than in those who
could be diagnosed with GDM according to only one of the two criteria (Fig 1).
Odds ratios were calculated under the dominant model. Higher OR values indicate the
significance of genetic predisposition in those pregnant women who meet both m99’WHO/
IADPSG GDM diagnostic criteria compared to all the other participating pregnant
individuals.
CDKAL1 rs7754840 and GCK rs799884 risk polymorphisms in GDM. Significant asso-
ciations were found with the intron variant (rs7754840) of the CDK5 regulatory subunit
associated protein 1 like 1 (CDKAL1) gene and with the rs1799884 intron variant of the Gluco-
kinase (GCK) gene after adjustment to maternal age and pre-pregnancy BMI covariates under
the dominant model (OR rs7754840 IADPSG: 1.51, p = 0.016 and OR rs1799884 IADPSG /
m99’WHO 1.4 / 1.56, p = 0.04/0.006). Results (ORs, MAFs and adjusted p-values) according
to the different diagnostic criteria are indicated in Table 2.
Protective polymorphisms, including a novel association signal with GDM. The
minor alleles of two common gene variants reduced the risk of developing GDM. A protec-
tive common polymorphism was identified as the rs7578326 SNP in the LOC646736/IRS1
region (OR for G allele [IADPSG/m99’ WHO]: 0.62/0,60, p = 0.001/0.006) under the
Table 1. Clinical characteristics of the pregnant population studied.
75g CH OGTT plasma
glucose values in GDM
group (mM)
75g CH OGTT plasma
glucose values in
Control group (mM)
Pre-pregnancy
BMI (kg/m2)
Age at delivery
(years)
Weight gain
during
pregnancy (kg)
HbA1c %6¼
(IFCC Unit-
mmol/mol)
0’ 60’# 120’ 0’ 60’# 120’ GDM Control GDM Control GDM Control GDM
Austria Mean 5.14 *˚ 9.68 * 7.38 *˚ 4.38 *˚ 6.80 * 5.42 * 28.31 * 23.40 * 32.04+˚ 30.51 * 9.68 9.47˚ 5.30 (34)
n = 183/147
(Cntrl/GDM)
95%CI of the
Difference (between
GDM and Cntrl study
groups)
0.63–
0.87
2.47–
3.28
1.61–
2.30
0.63–
0.87
2.47–
3.28
1.61–
2.30
2.72–7.09 0.08–2.97 -1.63–2.04 95%CI
(GDM only):
5.21–5.38
(33–35)
Hungary Mean 4.96 *˚ NA 8.72*˚ 4.52*˚ NA 5.45* 26.78* 23.32* 33.70*˚ 31.25* 8.72* 13.80*˚ 5.20 (33)
n = 408/195
(Cntrl/GDM)
95%CI of the
Difference (between
GDM and Cntrl study
groups)
0.34–
0.54
NA 3.06–
3.47
0.34–
0.54
NA 0.34–
0.54
2.55–4.36 1.54–3.36 -6.07–-4.07 95%CI
(GDM only):
5.10–5.30
(32–34)
Significant differences were found between the GDM and the Control groups as follows:
*p<10−4;
+p<0.05 (t—test or MWU).
Significant differences found between the Hungarian and Austrian study populations
˚ p<0.05.
# 60’ plasma glucose values at OGTT were only assessed in Austria.
6¼ HbA1c values were only determined in patients with GDM, but not in the controls.
doi:10.1371/journal.pone.0169781.t001
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dominant model and adjusting to age and pre-pregnancy BMI. Carrying a T allele of
rs13266634 C/T of the SLC30A8 gene significantly reduced the risk of developing GDM
under both diagnostic criteria under the additive model (OR [IADPSG/m99’ WHO]: 0.74/
0.71, p = 0.05/0.02) (Table 2).
A causative chain (when the association is not significant after age and BMI adjustments
only after age adjustment and the SNP associated effect on GDM develops via BMI) might
potentially be existing for a few gene variants (HNF1 homeobox B—HNF1B [TCF2]
-rs4430796, -rs7501939, clock circadian regulator—CLOCK -rs6832769,—“S2 Table”), how-
ever it needs confirmation with larger sample sizes and we may not yet report these associa-
tions as clinically meaningful causative chains due to the diminutive p-value differences after
the two adjustments.
Association between MTNR1B, GCK, TCF7L2, SLC30A8, LOC646736/
IRS1 gene variants and glycemic traits
Fasting plasma glucose levels. MTNR1B rs10830963 was the most significantly associated
SNP with the fasting plasma glucose levels (FPG) (mean effect size: 0.21 mmol/L increase,
p<5x10-4). The A allele of the rs1799884 polymorphism of the GCK gene was also significantly
associated with increased FPG levels (mean effect size 0.13mmol/L increase, p = 0.025). All
effect sizes are reported in Table 3 after adjustment to pre-pregnancy BMI and age covariates.
Two hour plasma glucose levels at OGTT. The MTNR1B rs10830963 was the most sig-
nificantly associated SNP with the 2 hour PG levels (mean effect size 0.605 mmol/L increase,
p = 5x10-4) after adjustments to pre-pregnancy BMI and age covariates and this remained
significant even when the adjusted p-value was further corrected to reduce FDR using the
Benjamini-Hochberg method (p = 0.044). In addition we found an association between the
rs7903146 polymorphism of the transcription factor 7-like 2 (TCF7L2) gene and 2 hour PG
values (mean effect size per T allele 0.25mmol/L increase, p = 0.027) after adjustment for pre-
pregnancy BMI and age. The rs7578326 SNP in the LOC646736/IRS1 region was associated
with decreased (effect size: -0.45 mmol/L, p = 0.0025) 2 hour plasma glucose levels, such as the
rs13266634 of the SLC30A8 gene (effect size per T allele: -0.26mmol/L, p = 0.02) (Table 3).
Fig 1. MTNR1B rs10830963 (true causal gene variant, risk allele G) associated odds ratios of
developing GDM by different diagnostic criteria.
doi:10.1371/journal.pone.0169781.g001
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Pre-pregnancy body mass index
All assessed SNPs of the Melanocortin 4 receptor (MC4R, rs10871777, rs571312, rs17782313)
were associated with higher pre-pregnancy BMI values at significant level after adjustment to
age and using the Benjamini-Hochberg FDR correction method. The LDL receptor related
protein 1B (LRP1B, rs2890652), Potassium voltage-gated channel subfamily J member 11
(KCNJ11, rs5219), CDK5 regulatory subunit associated protein 1 like 1 (CDKAL1, rs7754840)
and Fat mass and obesity (FTO, rs11642841) gene polymorphisms were associated with pre-
pregnancy BMI at suggestive levels (Table 4).
Discussion
We conducted a case-control genetic association study in a Caucasian population with 77 gene
variants that were either earlier reported to be associated with the GDM or with T2D due to
that GDM and T2D share similar genetic susceptibility background [18]. In addition a few
other gene variants (SNPs) with potential contribution to an important metabolic condition
were also assessed to detect associations with GDM or other related traits.
We found that the MTNR1B rs10830963/G allele had the most robust association with
GDM and also with glycemic traits, including both the FPG and the post-challenge (2 h) PG
values at 75g OGTT.
In a recent meta-analysis on GDM genetics the authors concluded that pooled OR for the
MTNR1B rs10830963 risk variant was lower in Asians (1.23) compared to Caucasians (1.49).
Table 3. Association of common gene variants with fasting and 120 minute plasma glucose values at oral glucose tolerance test (OGTT) in preg-
nant population.
SNP—
(major/
minor allele)
Reported Gene
(Symbol)
SNP locus
(chromosome:
base) ˚
Functional
class
MAF in 1000
Genomes in
European
population
Effect size* on the
FPG levels at
routine OGTT (24-
28th gw) in mmol/L
(Confidence
Interval**)
Effect size* on the 120
minute postchallenge
PG levels at routine
OGTT (24-28th gw) in
mmol/L (Confidence
Interval**)
Model p (adjusted
to BMI and
age—FPG /
120’ PG)
rs10830963
(C/G)
MTNR1B 11:92975544 intron
variant
0.29 0.205 (0.1065–
0.301)
0.605 (0.321–0.885) D <0.0005/
0.0005
rs7903146
(C/T)
TCF7L2 10:112998590 intron
variant
0.32 NS 0.25 (0.014–0.46) A NS / 0.027
rs1799884
(G/A)
GCK 7:44189469 upstream
variant
0.18 0.13 (0.02–0.24) NS D 0.025/ NS
rs7578326
(A/G)
lncRNA class
RNA gene in
the
LOC646736/
IRS1 region
2:227020653 intergenic
variant
0.35 NS -0.45 (-0.75 – -0.14) D NS/0.0025
rs13266634 SLC30A8 8: 117172544 intron
variant.
missense
0.28 NS -0.26 (-0.48 – 0.03) A NS / 0.02
The p-values were adjusted to age and pre-pregnancy body mass index (BMI).
* Effect size of different single nucleotide polymorphisms (SNPs) on FPG/120min and post challenge
PG values were calculated according to the genetic model applied.
Dominant model („D”): effect per carrying the reported minor allele.
Additive model („A”): effect per minor allele.
** Confidence intervals were calculated using bootstrap method.
˚ To indicate the chromosomal position the NCBI SNP database (release: 107.) was used.
doi:10.1371/journal.pone.0169781.t003
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Authors found that only in studies which included subjects with mean pre-pregnancy BMI
higher than 25 kg/m2, but not with lower mean pre-pregnancy BMI values the MTNR1B
rs10830963 risk variant was significantly associated with GDM [18]. Furthermore, in a recent
study with early intervention (diet, lifestyle intervention from the 13th gw) applied in high
GDM risk individuals (BMI>30kg/m2) only non-carriers of the risk allele G benefited from
the 3 months intervention assessed by PG values at routine OGTT suggesting that MTNR1B
rs10830963 variant could modify the efficacy of lifestyle interventions [35]. We found that the
rs10830963 MTNR1B gene variant is characterized with ORs between 1.84 and 1.64 (dominant
model), depending on the diagnostic criteria (IADPSG / m99’WHO) applied. Corroborating
reports of higher OR values for rs10830963/GMTNR1B found in Caucasians compared to
Asians are in accordance with these higher OR values we report here due to that our case
cohort was with a mean pre pregnancy BMI higher than 25kg/m2 (both in Austria and Hun-
gary) [9, 11, 14, 15, 17, 36, 37].
Table 4. Association of common gene variants with pre-pregnancy body mass index.
SNP—(major/
minor allele)
Reported
Gene
(Symbol)
SNP locus
(chromosome:
base) ˚
Gene function Functional
class
MAF in 1000
Genomes in
European
population
Genetic
model
Effect
size
p
(adjusted
to age)
rs10871777 (A/G) MC4R 18:60184530 Membrane-bound receptor and
member of the melanocortin
receptor family. Defects in this
gene are a cause of autosomal
dominant obesity.
intergenic
variant
0.25 A 1.083 0.0019
rs571312 (C/A) MC4R 18:60172536 intron variant 0.24 A 1.123 0.0019
rs17782313 (T/C) MC4R 18:60183864 intergenic
variant
0.24 A 1.103 0.0018
rs2890652 (T/C) LRP1B 2:142202362 Cell surface proteins that bind
and internalize ligands in the
process of receptor-mediated
endocytosis.
intergenic
variant
0.17 A -1.125 0.006
rs5215 (T/C) KCNJ11 11:17387083 Inward-rectifier type potassium
channel. Associated with the
sulfonylurea receptor SUR.
Mutations in this gene are a
cause of different types of
diabetes.
missense, nc
transcript
variant
0.35 A 0.604 0.048
rs5219 (C/T) KCNJ11 11:17388025 missense, nc
transcript
variant
0.35 A 0.696 0.022
rs7754840 (G/C) CDKAL1 6:20661019 Member of the
methylthiotransferase family.
Gene function is unknown. Gene
variants associated with
susceptibility to type 2 diabetes.
intron variant 0.32 D 1.157 0.007
rs7756992 (A/G) CDKAL1 6:20679478 intron variant 0.28 D 0.923 0.033
rs4712526 (T/A) CDKAL1 6:20662804 intron variant 0.32 D 1.008 0.018
rs11642841 (C/A) FTO 16:53811575 Exact function is unknown.
Association with body mass
index, obesity risk, and type 2
diabetes.
intron variant 0.41 A 0.529 0.07
MC4R: Melanocortin 4 Receptor
LRP1B Low Density Lipoprotein Receptor-Related Protein 1B
KCNJ11 Potassium Channel, Inwardly Rectifying Subfamily J, Member 11
CDKAL1:CDK5 Regulatory Subunit Associated Protein 1-Like 1
FTO: Fat Mass and Obesity-Associated Protein.
All p values were adjusted to age.
˚ To indicate the chromosomal position the NCBI SNP database (release: 107.) was used
D = dominant genetic model
A = additive genetic model
doi:10.1371/journal.pone.0169781.t004
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Accordingly, although several studies found that the rs10830963 MTNR1B variant was not
associated or only in subgroups associated with fasting and 2 hour glycemic traits, we consis-
tently found associations both with the fasting and post-challenge values with mean 0.21 and
0.61 mmol/L increases in PG levels at OGTT under the dominant model, respectively [11, 12,
14, 15].
Functionally it is important that the MTNR1B rs10830963 risk G allele is predicted to create
a recognition motif that matches the consensus sequences of neuronal differentiation 1 (NEU-
ROD1) and other transcription factors. This was suggested to be consistent with that the risk
G allele promotes islet MTNR1B expression [38] and the risk G allele also increases FOXA2-
bound enhancer activity in islet- and liver-derived cells.
The MTNR1B rs10830963 intron gene variant seems to be a credible causal gene variant
which is the driving association signal in contrast to other candidate SNPs (i.e. rs10830962)
that may be retrospectively interpreted as lead gene variants [11, 38].
MTNR1B gene encodes one of two high affinity forms of a receptor for melatonin, a pineal
gland hormone that regulates glucose metabolism by affecting circadian insulin secretion.
MTNR1B variants were associated with FPG values [25] and defective MTNR1BG-protein-cou-
pled receptor signaling on human beta cells decreased glucose sensitivity and impaired insulin
secretion [39]. The rs10830963 was associated with impaired first-phase insulin secretion and
decreased Homeostasis Model Assessment—Beta (HOMA-B) even in GDM populations [9, 40].
In a GWAS performed using over 2 million (imputed) initial gene variants Korean authors
reported the rs7754840 variant of CDKAL1 and also the rs10830963 variant of MTNR1B as risk
polymorphisms in GDM [11]. In our study on a Caucasian population however, CDKAL1
rs7754840 gene variant was only associated with GDM at a suggestive level. In contrast, the
minor, G allele of the rs7578326 SNP in the LOC646736/IRS1region is first reported here to
decrease the risk to develop GDM and to be associated with decreased fasting and 2 hour
plasma glucose levels. This protective effect of the minor, G allele is in concordance with prior
reports that identified the major, A allele as the risk allele for T2D in a large-scale association
analysis [27]. The IRS1 gene is localized over 500kb downstream of the LOC646736 genomic
region harboring the rs7578326 SNP and the genomic distance of linkage is typically less than
200kb. The LOC646736 locus and its relation to insulin resistance was characterized and
authors suggested clear genotype effects on insulin signaling in skeletal muscle, however did
not argue for causality of IRS1. Additional pathology might be possible, either via the transla-
tion of LOC646736 transcripts, however due to the lack of putative protein expression identifi-
cation in human tissues, it is possible that LOC646736 transcripts are linc (long intergenic
non-coding) RNAs that alter insulin signal transduction by either cis or trans regulation [41].
These mechanisms may potentially explain the protective effect of the (minor, G) variant of
the rs7578326 in the LOC646736 region we first describe in association with GDM develop-
ment and also with glycemic traits during pregnancy.
The other protective minor (T) variant identified in this analysis, the rs13266634 (C/T)
affects the amino acid residue 325 at the C-terminal of the zinc transporter 8 (ZnT8,
SLC30A8), which influences zinc homeostasis. In line with prior [11] reports in Asian popula-
tion our findings confirm the role of this SLC30A8 variant in Caucasian populations in GDM
development. Susceptibility likely evolves via the altered regulation of zinc homeostasis and
related changes in insulin production and beta cell function.
The other associations we found with glycemic traits such as the common rs1799884 pro-
moter variant of GCK (with increased FPG levels) and the rs7903146 variant of the TCF7L2
gene (with increased post-challenge PG levels) were reported in prior GDM genetic studies
[13, 42, 43].
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Regarding the overall architecture of genetic susceptibility of GDM, it should be recognized
that many of the gene variants we report here (MTNR1B,CDKAL1, SLC30A8, TCF7L2 and
potentially exerts similar effect) were reported to be associated with a reduced first phase insu-
lin secretion, while the second-phase insulin secretion remained intact [34, 44–47]. In contrast
to the above set of gene variants the rs7578326 SNP in the LOC646736/IRS1 region clearly
affected insulin sensitivity in previous studies [28, 41].
This genetic architecture of GDM predisposition might be especially relevant nowadays,
when clinical risk factors, such as higher pre-pregnancy BMI and age [3, 4] at pregnancy
become more prevalent resulting in increased insulin resistance and a need for a compensatory
increase in beta cell response and the latter might be substantially limited in genetically suscep-
tible individuals.
According to our findings (Fig 1) the most robust association of the causal MTNR1B variant
rs10830963, is more preponderant in those pregnant individuals who meet both the modified
99’ WHO and the IADPSG diagnostic criteria. In contrast it appears to have a more limited
role in determining the odds of disease development in those who could be diagnosed as GDM
only according to one of the above diagnostic recommendations, but not by the other. This
observation, the “clustering of genetic risk” might points towards precision medicine. Individ-
uals with a susceptible genetic background at risk for developing GDM could potentially bene-
fit from earlier diagnosis and treatment than the currently applied general routine testing
(OGTT between the 24-28th gestational week). On the other hand, those who might be diag-
nosed only according to one of the diagnostic recommendations, the role of lifestyle modifica-
tions, age at delivery and related epigenetics may be more substantial factors in determining
the odds of disease development (Fig 1).
Genetic markers could possibly also have everyday clinical utility due to that the accuracy
of methods predicting GDM and the identification of individuals who are at high risk of devel-
oping GDM with pre-pregnancy tests are still inadequate. The sensitivity of clinical risk factor
based GDM predictions (conventional risk factors: age, BMI, ethnicity, DM family history,
obstetric history—or novel approaches: circulating adiponectin) remains lower than 70%
[48, 49].
A limitation of our study is that the sample size allows only the identification of the most
robust genetic associations with GDM development (i.e.: OR>1.4) or related traits and did not
allow to detect other genetic susceptibility factors that may have a smaller, but still significant
effects on disease development or glycemic traits. These data would need confirmation a in a
well-powered replication follow-up study.
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